June 21, 2021 7:44am

Although caution is in the wind

Pre-open indications: 3 BUY – AGTC, BLCM, VYGR; 1 – SELL: ATHX; 1 SELL into Strength profit: CRSP; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! 

 

Dow futures are UP +0.43% (+142 points), S&P futures are UP +0.33% (+13 point) and NASDAQ futures are UP +0.31% (+44 points)

 

Stock futures were higher on Monday as the market and sector hope to rebound

European stocks were variable and shifting  

Asia-Pacific stocks dropped in Monday’s trade, however, led by a 3.3% plunge for Japan’s Nikkei 225.

 

Henry’omics:

Cell and gene therapy sector equities fell on Friday, as traders worried the Fed could start raising rates sooner than expected.

The Dow dropped 3.5% last week, while the S&P 500 flopped -1.9% and Nasdaq dipped -0.2%.

While the CBOE Volatility Index, or VIX, which represents the expected volatility of the U.S. stock market over the next 30 days, was up 16.6% Friday.

 

Data Docket: public appearances from Fed members on Monday. Bullard and Dallas Fed President Robert Kaplan are set to speak virtually on an Official Monetary and Financial Institutions Forum panel at 9:00 a.m. ET. New York Fed President John Williams is expected to deliver remarks at a Midsize Bank Coalition of America event this afternoon.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results to date …  https://www.regmedinvestors.com/articles/11628

 

Friday’s evening’s recap: “could have been worse. Witching Friday’s come and gladly go” …    https://www.regmedinvestors.com/articles/11962

  • The Nasdaq closed DOWN -130.97 points (-0.92%);
  • The IBB closed down -0.18% and XBI closed down -0.60%;
  • Sector volume INCREASED from the normal low with 10 of the 15-upside having higher than the 3-month average volume with the volume of 17 of 18-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +2.95 points or +16.62% at 20.70;
  • Friday’s percentage (%) of the 15-upside were +0.07% (BLFS) to +5.11% (RENE.L) while the 18-downside ranges from -0.21% (VSTM) to -4.73% (FATE);

Q2/21:

June: 8 positive and 5 negative close

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed flat at $1.21with 333 shares traded after Thursday’s -$0.09 to $1.21 with 735 shares traded after Wednesday’s +$0.089 to $1.30 with 205 shares traded, Tuesday’s -$0.039 to $1.21 with 10,703 shares traded and last Monday’s flat at $1.25 with 2,305 shares traded. WHO is trading this ZOMBIE?

Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?

Question#2: Will the annual meeting result in ANY news to/about the future of the company?

Question#3: WHY do I keep writing on BSTG – I was there and then SUDDENLY I wasn’t (there through NO fault of my own other than to UPHOLD the law) and saw WHAT they DID, WERE, KEPT on doing and CONTINUE to do - but, the REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

BUY:

Applied Genetic Technologies (AGTC) closed up +$0.04 to $4.44 after Thursday’s +$0.05 to $4.40 and has another positive +$0.01 or +0.23% pre-market indication.

Bellicum Pharmaceuticals (BLCM) closed up +$0.09 to $3.27 and has a positive +$0.12 or +3.67% pre-market indication.

Voyager Therapeutics (VYGR) closed down-$0.16 to $4.49 after Thursday’s -$0.17 to $4.65 with a negative -$0.01 or -0.22% pre-market indication.

 

SELL:

Athersys (ATHX) closed up +$0.02 to $1.57 with a Monday pre-market indication of -$0.05 or -3.18%

 

SELL – Lighten the “Load”:

CRISPR Therapeutics (CRSP) closed up +$0.56 to $127.83 after Thursday’s +$3.36 to $127.27 and Wednesday’s +$0.29 to $123.91 and has a positive +$1.16 or +0.89% pre-market indication and a +77.49% 52-week change.

 

The BOTTOM LINE: Not much has changed for me to “spout” … reverse volatility is BACK!

I continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.